|
|
|
|
|
Cefuroxime
drug data and news
Cefuroxime drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Cefuroxime | ||
| Brand Names/Synonyms | Ancef; Biofuroksym; Ceclor; Ceclor Cd; Cedax; Cefditoren; Cefizox; Cefotan; Ceftin; Ceftizoxime Sodium; Cefurax; Cefuril; Cefuroxim; Cefuroxime; Cefuroxime Axetil; Cefuroxime Free Acid; Cefuroxime Sodium; Cefuroxime Sodium Salt; Cefuroxime [Usan:Ban:Inn]; Cefuroxime and Dextrose in Duplex Container; Cefuroximo [Inn-Spanish]; Cefuroximum [Inn-Latin]; Cefzil; Cephuroxime; Ceptaz; Duricef; Elobact; Fortaz; Keflex; Keftab; Kefurox; Kefurox in Plastic Container; Kerurox; Mandol; Maxipime; Mefoxin; Monocid; Omnicef; Oraxim; Rocephin; Sharox; Tazicef; Vantin; Velosef; Zinacef; Zinacef Danmark; Zinacef in Plastic Container; Zinat; Zinnat | ||
| Indication | For the treatment of the following infections (respiratory, skin, soft tissue, urinary tract infections, ear, nose, throat infectsion) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A ß-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph. Also used to treat acute bacterial bronchitis in patients with COPD | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Cefuroxime, a second-generation cephalosporin, is used to treat severe upper and lower respiratory tract infections, skin infections, otitis media, and surgical prophylaxis. | ||
| Mechanism Of Action | Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor. | ||
| Cefuroxime News (When available) |
Rethinking UTI Prophylaxis Mar 1, 2006 Orbus Signs Licensing, Supply and Contract Manufacturing ... Feb 9, 2006 Orbus Signs Licensing, Supply and Contract Manufacturing ... 09 Feb 2006 GCGMH denies exclusive contract with drug firm Jan 28, 2006 Head-To-Head Study Shows More Elderly Patients With Community ... Jan 24, 2006 New safety scheme in Tallaght Hospital highlights common drug ... Jan 20, 2006 Hospital forges exclusive contract with drug company Jan 14, 2006 FDA Approves New Indication for Avelox (moxifloxacin HCl) for ... Nov 30, 2005 Oscient Pharmaceuticals Submits sNDA to FDA for Five-Day Treatment ... Nov 21, 2005 Orbus Signs Cefuroxime Axetil Licensing and Supply Agreement Sep 27, 2005 US party over for Indian pharma Oct 4, 2005 Clinical Data on FACTIVE(R) Tablets for ABS and AECB Presented at ... Oct 7, 2005 Ranbaxy guns for Pfizer's $12-b cholesterol drug — Generic cos ... Sep 12, 2005 Finding best generic drug Sep 19, 2005 Microbiological activity of telithromycin against Streptococcus ... Sep 21, 2005 Nitrous Oxide Does Not Increase Postop Infection Risk Sep 22, 2005 FDA Safety Labeling Changes: Cefuroxime, Zocor, Clozaril Aug 31, 2005 Lupin gets USFDA nod Aug 18, 2005 Acute Bacterial Sinusitis - Levaquin® (levofloxacin) FDA Approved ... Aug 15, 2005 Wockhardt gets USFDA nod for cefuroxime axetil Aug 2, 2005 Orbus Signs Cefuroxime Axetil Licensing Agreement Jul 25, 2005 Wockhardt gets USFDA nod for antibiotic Aug 5, 2005 Wockhardt jumps up on USFDA nod Aug 2, 2005 L&T plant in China Aug 2, 2005 Steroid Nasal Sprays Seem to Speed Sinusitis Recovery Jun 30, 2005 Schering-Plough Announces FDA Approval of AVELOX(R) (moxifloxacin ... Jun 30, 2005 Tick-Borne Disease Jun 26, 2005 Tick-Borne Disease Jun 26, 2005 Ketek(R) offers the first five-day antibiotic treatment for acute ... Apr 25, 2005 New Data Illustrate Geographic Variance in Rates of Drug Resistant ... Apr 5, 2005 GSK Re-Packages Product Feb 18, 2005 | ||
| Dosage Forms | POWDER; POWDER FOR SOLUTION; TABLET | ||
| Drug_Category | Anti-bacterial Agents; Cephalosporins; ATC:J01DC02 | ||
| Absorption | Well absorbed from the GI tract (bioavailability is 37-52%) | ||
| Interactions |
-->Interactions for Cefuroxime: Drug/Laboratory Test Interactions: A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedictís or Fehlingís solution or with ClinitestÒ tablets) but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving cefuroxime. Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method. | ||
| Toxicity | Allergic reactions might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic shock. | ||
| Organisms Affected | Enteric bacteria and other eubacteria | ||
| Chemical IUPAC Name | 4-(carbamoyloxymethyl)-8-[2-(2-furyl)-2-methoxyimino-acetyl]amino-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid | ||
| Chemical Formula | C16H16N4O8S | ||
| Molecular Weight | 424.386 g/mol | ||
| Smiles String | CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O | ||
| Melting Point | 216 °C | ||
| Water Solubility | 145 mg/mL (sodium salt) | ||
| State | Solid | ||
| LogP/Hphobicity | -0.921 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not available | ||
| Half Life | ~80 minutes | ||
| Protein Binding [%] | 50% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Cefuroxime.html http://www.rxlist.com/cgi/generic/cefurox.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00285 | ||
| CAS Registry Number | 55268-75-2 | ||
| KEGG Compound ID | C06894 | ||
| PubChem ID | SID:9111 | ||
| PharmGKB ID | PA448868 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2242657 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |